DexCom, Inc. (DXCM) Fundamental Checkup
DexCom, Inc. fundamental checkup using revenue growth, EPS growth, free cash flow, margins, ROIC, debt-to-equity, and TGMCharts chart exhibits as of September 8, 2026.
By TGMCharts Research · Data as of · Updated
DexCom, Inc. exhibits robust long-term expansion, with a five-year revenue CAGR of 18.03% and an EPS CAGR of 10.31%, though its current market price sits above the analyst DCF (FMP) estimate.
The fundamental thesis is supported by a cash-flow conversion rate of 69.49% and an ROIC of 21.71%, while a current ratio of 1.73x and debt-to-equity of 0.53x preserve balance-sheet flexibility.
- DexCom, Inc. has market cap of $31.90B and closed at $84.53 on September 8, 2026.
- Five-year revenue CAGR is 18.03% and five-year EPS CAGR is 10.31%.
- Five-year free-cash-flow CAGR is 69.49%.
- Net margin is 20.12% and ROIC is 21.71%.
- Current ratio is 1.73x and debt-to-equity is 0.53x.
Fundamental snapshot
The valuation, growth, profitability, and balance-sheet facts behind the checkup.
A Unified View of Reinvestment and Growth Quality
Evaluating DexCom, Inc. requires looking beyond isolated metrics to see if top-line momentum, cash conversion, and balance-sheet health tell a consistent story. With the stock closing at $84.53 on September 8, 2026, the business must defend its current valuation through operational performance. This analysis dissects the underlying financial data to determine if the operational reality matches the market pricing.
The core of the thesis rests on a five-year revenue CAGR of 18.03% alongside a five-year EPS CAGR of 10.31%. When paired with a five-year free-cash-flow CAGR of 69.49%, these figures suggest a highly efficient business model. However, a comprehensive fundamental assessment must test whether these historical growth rates remain sustainable under current balance-sheet and margin conditions.
Current compounder snapshot · DXCM
Live supporting context; not part of the article's frozen 2026-09-08 evidence snapshot.
- Score
- 57/100
- 10Y CAGR
- 27.8%
- Median YoY
- 24.6%
- YoY volatility
- σ 12.0pp· uneven
- Quarters ≥ 20%
- 28 of 40
- Negative quarters
- 0
- Valuation vs own 10Y history
- P/S 6.9x · 10Y median 12.5x · 13th percentile · as of Sep 4, 2026
How this score is computed
- Quarters at or above 20%: 28 of 40 → 28 of 40 pts
- Steadiness (typical swing 12.0pp) → 16.4 of 25 pts
- Pace (median 24.6% YoY) → 12.8 of 20 pts
- Latest quarter (13.1% YoY) → 0 of 15 pts
- Score: 57 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Operational Footprint in the Medical Technology Sector
Operating within the competitive Healthcare sector, the company represents a large-cap medical technology player with a market capitalization of $31.90B. This scale demands substantial ongoing capital investment to maintain its market position and support its growth trajectory. The operational snapshot below provides a consolidated view of the key financial pillars—growth, efficiency, and leverage—before we examine individual trends.
Fundamental evidence table
A compact cross-check of valuation, growth, quality, and financial flexibility.
DXCM revenue
Revenue history shows whether the business has been expanding before margins and per-share metrics are considered.
Five-year revenue CAGR: 18.03%. This is endpoint-to-endpoint across the five-year window — a depressed start year can inflate it, so read it against the recent bars.
Five-year revenue CAGR of 18.03% is the top-line test. A fundamental checkup becomes more durable when revenue growth is paired with earnings growth instead of depending only on margin expansion.
Translating Top-Line Momentum Into Shareholder Returns
A critical test of any growth business is whether top-line expansion successfully translates into bottom-line profitability for shareholders. The company has achieved a five-year revenue CAGR of 18.03%, representing steady expansion of its business footprint. However, the five-year EPS CAGR of 10.31% shows that earnings per share have grown at a slower rate than total sales over this multi-year period.
This divergence between revenue and earnings growth suggests that the business has faced rising operating costs or capital requirements that have diluted top-line gains. While net income and EPS are rising in recent trailing twelve-month periods, the historical gap highlights the importance of monitoring operating expenses. Investors must verify whether recent efficiency gains can narrow this structural growth gap over the long term.
DXCM EPS
EPS history shows how much of the business growth has reached shareholders.
Five-year EPS CAGR: 10.31%. This is endpoint-to-endpoint across the five-year window — a depressed or negative start year can inflate it, so read it against the recent bars.
Five-year EPS CAGR of 10.31% is the shareholder conversion check. If EPS grows faster than revenue, the note should ask whether that came from margin quality, buybacks, or a temporary base effect.
Strong Cash Generation Validates Reported Earnings
While earnings figures can be influenced by non-cash accounting adjustments, free cash flow provides an objective measure of the cash actually generated by the business. The company has delivered an exceptional five-year free-cash-flow CAGR of 69.49%. This rapid cash expansion significantly outpaces both revenue and EPS growth, indicating high-quality earnings conversion.
This strong cash-flow trajectory suggests that the business has become increasingly efficient at managing its working capital and capital expenditures relative to its operating profit. Rising free cash flow provides the company with the financial resources needed to fund internal research and development, pursue strategic acquisitions, or reduce outstanding debt without relying on dilutive equity issuance.
DXCM free cash flow
Free cash flow checks whether earnings are converting into owner cash.
Five-year free-cash-flow CAGR: 69.49%. This is endpoint-to-endpoint across the five-year window — a depressed or negative start year can inflate it, so read it against the recent bars.
Free-cash-flow CAGR of 69.49% is the counterweight to the EPS story. If cash flow lags earnings, the quality of the fundamental setup deserves a more cautious reading.
High Returns on Capital Underpin Operational Efficiency
The durability of the company's growth depends heavily on its underlying profitability margins and return on capital. The business currently operates with a net margin of 20.12%, demonstrating solid profitability relative to its total sales. This margin level ensures that a meaningful portion of each dollar of revenue is retained as net profit.
Furthermore, the company boasts a return on invested capital (ROIC) of 21.71%. This high ROIC indicates that the business generates excellent returns on the debt and equity capital deployed within its operations. A high return on capital is a strong indicator of reinvestment efficiency, showing that the company can compound its earnings internally as it continues to expand.
DXCM net margin
Net margin is the operating-quality check behind the growth record.
Net margin (TTM): 20.12%. The bars below are reported fiscal periods (quarterly where available).
Net margin of 20.12% shows how much revenue becomes profit. The checkup is stronger when margin quality supports EPS growth rather than simply flattering one recent period.
DXCM ROIC
ROIC tests whether the business earns enough on reinvested capital to deserve attention.
Latest ROIC: 21.71%.
ROIC of 21.71% is the reinvestment-quality check. A business with stronger returns can support a better long-term read even when the valuation is not obviously cheap.
Moderate Leverage and Solid Liquidity Provide Safety
Financial flexibility serves as the essential guardrail protecting the company's growth initiatives during economic or industry downturns. The company maintains a current ratio of 1.73x, indicating a healthy buffer of short-term assets relative to its near-term liabilities. This liquidity position ensures the business can meet its immediate operational commitments without friction.
On the liabilities side, the debt-to-equity ratio stands at 0.53x. This moderate level of leverage suggests that while the company utilizes debt to optimize its capital structure, it remains well within safe limits. This balanced approach to leverage preserves the company's creditworthiness and ensures it retains access to capital markets if expansion opportunities arise.
DXCM debt-to-equity Chart
Debt-to-equity keeps the checkup honest about balance-sheet flexibility.
Latest debt-to-equity ratio: 0.53x.
Debt-to-equity of 0.53x and current ratio of 1.73x are the balance-sheet checks. They matter because growth and margins are less valuable if financial flexibility is narrowing.
Market Price Demands Sustained Operational Execution
The stock currently trades at a price-to-earnings (P/E) ratio of 34.74x, which corresponds to an earnings yield of 2.88%. This multiple indicates that the market has priced in high expectations for future growth and profitability. Consequently, the current market price sits above the analyst DCF (FMP) estimate, leaving a negative margin of safety relative to conservative valuation models.
With a P/E multiple at this level, the company has very little room for operational missteps. To justify this valuation, the business must not only maintain its current growth trajectory but also work to close the historical gap between its revenue and earnings growth rates. Any deceleration in sales or compression in margins could lead to significant multiple contraction.
DXCM Price Chart
Latest close: $84.53 as of September 8, 2026.
The close at $84.53 is not the conclusion, but it is the market reference point. The fundamental read has to explain whether growth, margins, and balance-sheet support justify the price investors are paying.
Weighing Cash-Flow Strength Against Valuation Risks
The primary bull case for the company rests on its exceptional cash-flow generation and high capital efficiency. A five-year free-cash-flow CAGR of 69.49% combined with an ROIC of 21.71% indicates a highly profitable business model that is compounding internal value rapidly. This financial strength is supported by a clean balance sheet with moderate leverage.
Conversely, the bear case is centered on valuation and the historical lag in earnings conversion. With EPS growth of 10.31% trailing revenue growth of 18.03% over five years, the business has historically struggled to convert sales expansion into proportional shareholder profits. If operational costs rise or capital expenditure requirements intensify, the premium valuation multiple will face downward pressure.
Bull and bear case
Fundamental support
- Five-year revenue CAGR of 18.03% and five-year EPS CAGR of 10.31% support the business case.
- Net margin of 20.12% and ROIC of 21.71% are the quality checks behind the thesis.
Fundamental pressure
- Free-cash-flow CAGR of 69.49% can weaken the read if it falls away from EPS growth.
- Debt-to-equity of 0.53x and current ratio of 1.73x are the balance-sheet checks that can change the view.
Monitoring Key Operational and Balance Sheet Metrics
In conclusion, the company presents a high-growth, cash-generative profile, but one that is accompanied by a demanding market valuation. The final fundamental read remains balanced: the operational metrics are highly robust, but the current price leaves no margin of safety for new capital. This assessment would adjust if future quarterly reports show a material shift in growth or margin trends.
Going forward, the key indicators to monitor are the sustainability of the five-year revenue CAGR of 18.03% and whether the free-cash-flow growth rate begins to align more closely with net income. Any deterioration in the current ROIC of 21.71% or a significant increase in the debt-to-equity ratio would signal a weakening of the core investment thesis.
FAQ
What is the fundamental read on DXCM?
DexCom, Inc. is judged through revenue growth of 18.03%, EPS growth of 10.31%, free-cash-flow growth of 69.49%, net margin of 20.12%, and ROIC of 21.71%.
Which DXCM fundamental metric matters most?
No single metric carries the article. The checkup requires growth, cash conversion, profitability quality, balance-sheet flexibility, and valuation to be read together.
When should this DXCM checkup refresh?
Its figures are as of September 8, 2026, the note's dated snapshot; a note whose figures stop verifying against reported data is corrected or unpublished.
What would change our mind
- Revenue growth moving away from the current five-year CAGR of 18.03%.
- Free-cash-flow growth drifting away from five-year EPS CAGR of 10.31%.
- ROIC or balance-sheet flexibility weakening from ROIC of 21.71% and debt-to-equity of 0.53x.
The bottom line
DexCom, Inc. fundamental research note from TGMCharts Research, grounded in a dated fundamentals snapshot, chart exhibits, and linked source facts.
Read next: DXCM fundamentalsContinue with DexCom, Inc.'s full stock page.How we checked this researchShowHide
Data snapshot · By TGMCharts Research.
Every number in this note comes from data we compute and store ourselves from the company's reported figures, plus verbatim excerpts from its SEC filings. When a value isn't available we say so — we never fill gaps with estimates.
Latest filing excerpt
10-Q · filed 2026-07-30 · period 2026-06-30 · SEC EDGAR source
- “Selling, general and administrative expense Selling, general and administrative expense increased primarily due to $12.1 million in incremental investments in advertising and marketing costs, $6.7 million in higher compensation and related costs, and $6.3 million in higher facilities-related costs.”
- “Other income (expense), net Other income (expense), net, decreased primarily due to $11.1 million in lower interest and dividend income, $10.3 million in net foreign currency losses, and $9.6 million in net losses on equity investments.”
- “Selling, general and administrative expense Selling, general and administrative expense increased primarily due to $27.2 million in incremental investments in advertising and marketing costs, $22.6 million in higher compensation and related costs, and $11.5 million in higher facilities-related costs.”
- “Other income, net Other income, net, decreased primarily due to $20.1 million in lower interest and dividend income and $13.6 million in net foreign currency losses.”
Source pages
Exhibit sources
Research trail
Every number, checked
Every numeric or dated claim in this note was checked against our stored company data before publishing — each figure below links to the page it comes from.